secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001510964-22-000085
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q3 2022 revenue down 27% YoY to $3.8M, operating loss narrowed to $0.9M
--------------------------------------------------------------------------------

- Revenue $3.8M, down 27% from $5.1M; gross margin 41.6% vs 46.2%.
- Operating loss improved to $0.9M from $3.0M; negative adjusted EBITDA $1.2M vs $2.7M.
- Cash balance $1.1M; extinguished entire outstanding convertible debt.
- Preliminary approval of settlement of six shareholder derivative lawsuits; continues strategic review including M&A.
- Launched PlusCBD Reserve Collection; maintains #1 hemp extract brand in natural channel per SPINS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000151096422000085/0001510964-22-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000151096422000085/cvsi-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001510964-22-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer